CIK 0001360214 · Large accelerated filer
HARROW, INC.
Sign in to watch- Ticker
- HROW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450567010
- Phone
- 615.733.4731
- Business address
- 1A BURTON HILLS BLVD, SUITE 200, NASHVILLE, TN
- Former names
- HARROW HEALTH, INC., Imprimis Pharmaceuticals, Inc., TRANSDEL PHARMACEUTICALS INC, Bywater Resources, Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 43 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-07 | SAHAREK JOHN P. CEO & President, ImprimisRx | Shares withheld for taxes | −109,475 | $23.09 | $2.5M | 467,388 |
| 2025-04-07 | BAUM MARK L Chief Executive Officer | Shares withheld for taxes | −300,363 | $23.09 | $6.9M | 2,599,462 |
| 2025-04-03 | BOLL ANDREW R. Chief Financial Officer | Option exercise | +346,500 | 914,589 | ||
| 2025-04-03 | BOLL ANDREW R. Chief Financial Officer | Option exercise · Performance Stock Unit | −346,500 | 0 | ||
| 2025-04-03 | SAHAREK JOHN P. CEO & President, ImprimisRx | Option exercise | +277,200 | 576,863 | ||
| 2025-04-03 | SAHAREK JOHN P. CEO & President, ImprimisRx | Option exercise · Performance Stock Unit | −277,200 | 0 | ||
| 2025-04-03 | BAUM MARK L Chief Executive Officer | Option exercise | +762,300 | 2,899,825 | ||
| 2025-04-03 | BAUM MARK L Chief Executive Officer | Option exercise · Performance Stock Unit | −762,300 | 0 | ||
| 2025-03-24 | Opaleye Management Inc. 10% owner | Sale | −5,000 | $30.01 | $150K | 140,000 |
| 2025-03-18 | Opaleye Management Inc. 10% owner | Sale | −5,000 | $29.64 | $148K | 145,000 |
| 2025-03-18 | Opaleye Management Inc. 10% owner | Sale | −5,000 | $30.01 | $150K | 140,000 |
| 2025-03-18 | Opaleye Management Inc. 10% owner | Sale | −5,000 | $29.64 | $148K | 145,000 |
| 2025-02-28 | Opaleye Management Inc. 10% owner | Sale | −5,000 | $28.05 | $140K | 150,000 |
| 2025-01-22 | Opaleye Management Inc. 10% owner | Sale | −20,000 | $35.59 | $712K | 155,000 |
| 2025-01-06 | Shojaei Amir CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2024-09-11 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise | +90,000 | $7.37 | $663K | 344,803 |
| 2024-09-11 | SAHAREK JOHN P. CEO of ImprimisRx | Shares withheld for taxes | −45,140 | $41.37 | $1.9M | 299,663 |
| 2024-09-11 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise · Stock Option (Right to Buy) | −90,000 | 0 | ||
| 2024-06-14 | Sternberg Perry J. Director | Grant or award · RSU | +8,347 | 8,347 | ||
| 2024-06-14 | Makary Martin A. Director | Grant or award · RSU | +8,347 | 8,347 |
Page 3 of 17 · 336 trades